Genmab — December 2016
-
“MRD negativity was consistently higher in patients treated in daratumumab,” Avet-Loiseau said, adding that patients treated with the drug reached MRD negativity as soon as 3 months. “We still see patients achieving MRD negativity.”
High-risk patients also achieved MRD negative status in both studies, according to Avet-Loiseau. Eighteen percent of high-risk patients in the POLLUX study and 14% of those in CASTOR achieved MRD negativity.
“The most important factor in achieving PFS is MRD negati
-
"unprecedented".
-
Winkel lovede os flotte data på MRD negativitet på ASH. Det har vi så sandelig fået nu.
-
Det må man sige.
-
Minimal tilbageværende sygdom.
-
Altså at patienten testes negativt for det.
-
-
Det ligner et kæmpe nej i Italien, det kan godt give kraftige døninger i morgen! Desværre!
-
Læs lige interview med Plesner igen - link fra Farfar1952 3/12 http://haematologisktidsskrift.dk/sygdomme/myeloma/222-daratumumab-rundt-pa-365-dage.html?user=al9hjgTY&passw=$2y$10$yNq10FjK8pizHgW/RWm.9O5hsjudYVck2.3tpOkerbTe4.Q8m7ecq
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind